通心络胶囊联合沙库巴曲缬沙坦治疗左心相关性肺动脉高压的临床效果

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (36 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察通心络胶囊联合沙库巴曲缬沙坦治疗左心相关性肺动脉高压（PH-LHD）的临床效果。方法选取2019年8～12月我院收治的108 例PH-LHD 患者，按入院顺序分为对照组、观察A 组、观察B 组，各36 例。三组均给予常规治疗，对照组在常规治疗的基础上给予缬沙坦，观察A 组在常规治疗的基础上给予沙库巴曲缬沙坦，观察B 组在常规治疗的基础上给予沙库巴曲缬沙坦联合通心络胶囊。比较三组治疗3 个月后的临床疗效、动脉血氧分压（PaO2）、肺动脉压[肺动脉收缩压（PASP）、肺动脉舒张压（PADP）]。结果观察B 组的治疗有效率均高于观察A 组与对照组，差异有统计学意义（P＜0.05）。三组治疗后的PaO2 水平均高于治疗前，差异有统计学意义（P＜0.05）。观察B 组治疗后的PaO2 水平高于观察A 组与对照组，差异有统计学意义（P＜0.05）。三组治疗后的PASP、PADP 水平均低于治疗前，差异有统计学意义（P＜0.05）。观察B 组治疗后的PASP、PADP 水平低于观察A 组与对照组，差异有统计学意义（P＜0.05）。结论通心络胶囊联合沙库巴曲缬沙坦治疗PH-LHD 可提高临床效果，改善动脉PaO2 及肺动脉压，值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：左心相关性肺动脉高压, 通心络胶囊, 沙库巴曲缬沙坦, 动脉血氧分压, 肺动脉收缩压, 肺动脉舒张压

Abstract：Objective To observe the clinical effect of Tongxinluo Capsules combined with Sacubitril and Valsartan in the treatment of pulmonary hypertension due to left heart disease (PH-LHD). Methods A total of 108 patients with PH-LHD who admitted in our hospital from August to December 2019 were selected and randomly divided into the control group, the observation group A and the observation group B, with 36 cases in each group. Three groups were given routine treatment, the control group was given Valsartan based on routine treatment, the observation group A was given Sacubitril and Valsartan based on routine treatment, and the observation group B was treated with Sacubitril and Valsartan combined with Tongxinluo Capsules based on routine treatment. After treatment for 3 months, the clinical efficacy, arterial partial pressure of oxygen (PaO2), pulmonary arterial pressure (pulmonary arterial systolic pressure[PASP], pulmonary arterial diastolic pressure [PADP]) were compared among the three groups. Results The effective rate of the observation group B were higher than those of the observation group A and the control group, the differences were statistically significant (P＜0.05). The level of PaO2 in the three groups after treatment were higher than those before treatment, the differences were statistically significant (P＜0.05). The level of PaO2 in the observation group B was higher than that in the observation group A and the control group, the differences were statistically significant (P＜0.05).After treatment, the level of PASP and PADP of the three groups were lower than those before treatment, the differences were statistically significant (P＜0.05). The levels of PASP and PADP in the observation group B were lower than those in the observation group A and the control group, the differences were statistically significant (P＜0.05). Conclusion Tongxinluo capsule combined with Sacubitril and Valsartan in the treatment of PH-LHD can increase clinical efficacy, and improve PaO2 and pulmonary arterial pressure, which is worthy of clinical promotion and application.

Key words： Pulmonary hypertension due to left heart disease Tongxinluo Capsules Sacubitril and Valsartan;Arterial partial pressure of oxygen Pulmonary arterial systolic pressure Pulmonary arterial diastolic pressure

收稿日期: 2020-02-26

基金资助:江西省中医药科研课题（2019A407）

作者简介: 汤曾耀（1987-），男，江西九江人，硕士，主治医师，研究方向：心血管内科

引用本文:

汤曾耀；梅寒颖；刘继文；王新旺；朱保成；刘玉连. 通心络胶囊联合沙库巴曲缬沙坦治疗左心相关性肺动脉高压的临床效果[J]. 中国当代医药, 2020, 27(29): 29-31.
TANG Zeng-yao MEI Han-ying LIU Ji-wen WANG Xin-wang ZHU Bao-cheng LIU Yu-lian. Clinical effect of Tongxinluo Capsules combined with Sacubitril and Valsartan in the treatment of pulmonary hypertension due to left heart disease. 中国当代医药, 2020, 27(29): 29-31.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I29/29

[1]	江慧慧，周思静，王苒.左心疾病相关性肺动脉高压发病机制研究进展[J].临床肺科杂志，2019，24（8）：1518-1520.
[2]	中华医学会心血管病学分会心力衰竭学组.中国心力衰竭诊断和治疗指南201[J].中华心血管病杂志，2018，46（10）：760-789.
[3]	任勇，吴金如，汤永谦，等.缬沙坦治疗慢阻肺并肺动脉高压的疗效分析[J].临床肺科杂志，2016，21（7）：1239-1241.
[4]	朱玉萍.缬沙坦治疗慢性阻塞性肺疾病并肺动脉高压的疗效分析[J].吉林医学，2017，38（9）：1743.
[5]	李德民，张金盈.低剂量沙库巴曲缬沙坦治疗扩张型心肌病心力衰竭的短期效果观察[J].中国实用医刊，2019，46（5）：115-118.
[6]	戴雯莉，吴翔宇，王苏，等.沙库巴曲缬沙坦治疗慢性充血性心力衰竭患者的临床研究[J].中国医药，2019，14（9）：1297-1301.
[7]	周健华.沙库巴曲/缬沙坦的研究进展[J].中国药师，2019，22（10）：1902-1905.
[8]	闫贤良，高玉龙，陶英，等.沙库巴曲缬沙坦钠在心力衰竭患者中的临床疗效观察[J].中国循证心血管医学杂志，2019，11（10）：1248-1250.
[9]	普顺华，关英霞，杨志刚，等.沙库巴曲缬沙坦治疗左心室射血分数降低心力衰竭患者的临床疗效观察[J].中国心血管病研究，2019，17（3）：266-269.
[10]	张相杰，黄文平，许有凡.沙库巴曲缬沙坦和盐酸贝那普利片对心力衰竭患者心室重塑、炎症因子的影响[J].实用医学杂志，2019，35（5）：795-799.
[11]	程小兵.沙库巴曲缬沙坦治疗心力衰竭的作用机制、临床应用及指南推荐意见[J].实用心脑肺血管病杂志，2019，27（9）：1-4.
[12]	刘旭帮，魏娟玲.中西医结合治疗慢性心力衰竭78 例临床观察[J].中国民族民间医药，2019，28（23）：100-101.
[13]	刘娜.通心络胶囊联合法舒地尔治疗慢性阻塞性肺病患者肺动脉高压的疗效[J].医疗装备，2016，29（15）：100-101.
[14]	黄瑞.美托洛尔联合通心络治疗冠心病心力衰竭的临床效果观察[J].医药前沿，2019，9（28）：107-108.
[15]	张孝飞，唐超，魏萍，等.通心络胶囊联合阿魏酸钠治疗老年慢性肺心病急性加重期的临床研究[J].现代药物与临床，2019，34（3）：729-733.